duchenn
muscular
dystrophi
dmd
sever
muscl
wast
disord
caus
disrupt
dystrophin
mrna
read
frame
result
outoffram
transcript
nonfunct
dystrophin
past
decad
number
new
treatment
dmd
investig
antisens
oligonucleotid
ao
mediat
splice
correct
one
promis
ao
modul
dystrophin
premrna
splice
specif
restor
read
frame
dystrophin
gene
via
exon
skip
therefor
gener
truncat
semifunct
dystrophin
protein
isoform
vivo
studi
dmd
mous
model
mdx
shown
system
deliveri
nake
phosphorodiamid
morpholino
oligom
pmo
ao
capabl
restor
signific
dystrophin
protein
cardiac
muscl
notabl
even
direct
intracardiac
inject
nake
ao
result
low
exon
although
clinic
trial
chemistri
shown
great
promis
still
need
optim
improv
ao
deliveri
skelet
muscl
heart
critic
respiratori
cardiac
major
caus
prematur
death
dmd
patient
particular
cardiomyopathi
becom
clinic
appar
year
age
exhibit
dmd
patient
age
studi
shown
restor
dystrophin
respiratori
muscl
improv
cardiac
function
absenc
restor
dystrophin
protein
concern
improv
skelet
muscl
function
absenc
cardiac
correct
may
worsen
cardiac
diseas
progress
due
increas
cardiac
work
therefor
highli
desir
futur
therapi
endeavor
restor
dystrophin
cardiac
well
skelet
muscl
cellpenetr
peptid
cpp
may
readili
conjug
charg
neutral
ao
pmo
shown
potenti
improv
system
deliveri
cpp
contain
cation
amino
acid
particularli
multipl
arginin
highli
effect
enhanc
ao
deliveri
due
uniqu
abil
deliv
associ
cargo
across
plasma
endosom
variou
argininerich
peptid
found
particularli
effect
deliveri
charg
neutral
lead
system
dystrophin
product
howev
dystrophin
protein
restor
heart
typic
requir
andor
high
dose
deriv
cpp
penetratin
origin
deriv
homeobox
peptid
drosophila
also
investig
name
contain
six
addit
employ
lead
peptid
seri
peptid
nucleic
acidspmo
intern
peptid
pip
deriv
found
much
stabl
serum
two
pip
peptid
conjug
dystrophin
exon
peptid
nucleic
acid
ao
shown
capabl
induc
strong
exon
skip
dystrophin
posit
fibr
follow
intramuscular
inject
tibiali
anterior
ta
muscl
mdx
mous
optim
peptid
seri
carri
conjug
pmo
identifi
effici
peptidepmo
conjug
capabl
induc
high
level
exon
skip
dystrophin
restor
bodi
wide
includ
heart
follow
singl
dose
intraven
structur
compris
hydrophob
core
region
flank
side
argininerich
domain
contain
aminohexanoyl
x
b
spacer
analog
previou
argininerich
b
thought
high
arginin
content
contribut
overal
deliveri
effici
muscl
tissu
wherea
hydrophob
region
might
import
heart
muscl
deliveri
report
result
seri
mutat
hydrophob
core
region
peptid
central
core
region
amino
acid
sequenc
revers
scrambl
partial
delet
chang
affect
level
exon
skip
dystrophin
restor
multipl
muscl
group
includ
heart
follow
singl
low
dose
intraven
inject
correspond
conjug
result
show
core
length
amino
acid
appear
essenti
heart
dystrophin
product
sinc
reduct
core
length
reduc
cardiac
activ
unexpectedli
arginin
residu
toler
one
posit
hydrophob
core
two
arginin
residu
toler
arginin
differ
posit
surprisingli
skelet
dystrophin
product
also
reduc
two
latter
case
previou
lead
pip
seri
cpp
contain
two
argininerich
flank
region
central
hydrophob
core
probe
composit
requir
hydrophob
core
mainten
good
heart
dystrophin
product
synthes
rang
deriv
peptid
af
figur
mutat
made
hydrophob
core
region
exampl
scrambl
partial
delet
core
region
peptid
peptid
contain
number
arginin
residu
flank
sequenc
except
peptid
conjug
pmo
complementari
dystrophin
exon
previous
valid
exon
skip
mdx
mice
contrast
method
conjug
end
pmo
utilis
conjug
prepar
conjug
end
pmo
ctermin
carboxyl
acid
moieti
pip
peptid
figur
report
signific
differ
vivo
dystrophin
product
exon
skip
activ
conjug
end
pmo
end
therefor
chose
utilis
end
conjug
exon
skip
potenti
conjug
evalu
differenti
mous
mdx
myotub
absenc
transfect
agent
figur
concentr
rang
show
exon
skip
activ
cultur
muscl
cell
similar
construct
includ
result
differ
previou
flank
argininerich
sequenc
mostli
contain
fix
number
arginin
residu
space
vari
altern
placement
aminohexanoyl
unit
result
small
variat
exon
skip
activ
correl
well
vivo
activ
case
sequenc
flank
argininerich
sequenc
ident
except
ident
except
one
arginin
immedi
preced
core
displac
second
posit
core
result
demonstr
cellular
exon
skip
activ
depend
sequenc
length
hydrophob
core
note
previous
shown
major
chang
vitro
exon
skip
activ
correl
instead
total
number
arginin
given
potenc
heart
tissu
aim
alter
sequenc
hydrophob
core
whilst
maintain
length
identifi
peptid
might
effici
lower
dose
modif
includ
invers
hydrophob
region
substitut
tyrosin
isoleucin
substitut
glutamin
sequenc
displac
arginin
immedi
flank
core
first
argininerich
flank
region
scrambl
hydrophob
core
sequenc
peptidepmo
conjug
administ
mdx
mice
singl
mgkg
intraven
inject
via
tail
vein
tissu
harvest
week
later
assess
activ
rna
protein
level
immunohistochem
stain
dystrophin
express
core
reveal
high
level
dystrophin
product
skelet
muscl
includ
ta
diaphragm
heart
figur
immunohistochem
stain
quantif
figur
b
perform
previous
achiev
take
four
repres
frame
dystrophin
stain
correl
laminin
stain
section
n
quadricep
diaphragm
heart
peptidepmo
treatment
untreat
mdx
treat
mdx
mice
normal
mice
method
allow
comparison
stain
intens
dystrophin
sarcolemma
rel
laminin
treatment
group
intens
ratio
normal
sampl
region
interest
sarcolemma
region
treatment
group
plot
scatter
graph
rel
intens
valu
obtain
four
core
conjug
significantli
differ
untreat
mdx
mice
quadricep
diaphragm
figur
tabl
similar
dystrophin
restor
level
quadricep
percent
recoveri
figur
diaphragm
treatment
except
higher
recoveri
score
diaphragm
rs
rang
figur
core
mice
exhibit
high
dystrophin
intens
valu
heart
except
statist
signific
compar
mdx
p
tabl
conjug
display
highest
recoveri
score
observ
figur
rs
respect
close
follow
rs
rs
directli
compar
treatment
significantli
better
heart
tabl
core
also
shown
restor
dystrophin
complex
protein
name
neuron
nitric
oxid
synthas
illustr
immunohistochem
stain
ta
muscl
supplementari
figur
pcr
western
blot
analys
exhibit
similar
result
immunostain
revers
transcriptionpcr
rtpcr
repres
imag
figur
illustr
high
exon
skip
effici
tissu
analyz
better
shown
quantit
realtim
pcr
qrtpcr
result
quadricep
diaphragm
heart
figur
delta
transcript
normal
total
dystrophin
muscl
group
n
quantif
data
reveal
similar
level
skip
quadricep
mice
data
trend
suggest
show
highest
exon
skip
diaphragm
highest
heart
splice
mean
valu
see
supplementari
figur
western
blot
figur
perform
tissu
mous
quantifi
control
result
averag
present
supplementari
figur
conjug
exhibit
highest
dystrophin
protein
restor
ta
quadricep
muscl
level
dystrophin
restor
diaphragm
uniform
across
treatment
wherea
case
heart
conjug
show
highest
dystrophin
restor
protein
restor
measur
immunohistochem
stain
consist
higher
protein
restor
calcul
western
blot
analysi
differ
may
attribut
differ
hous
protein
use
ie
dystrophin
restor
quantifi
immunohistochem
stain
normal
laminin
wherea
western
blot
analysi
use
normalis
quantif
western
blot
recent
report
dystrophin
current
use
chemiluminesc
method
may
therefor
judici
give
greater
weight
trend
dystrophin
protein
level
reveal
western
blot
rather
absolut
valu
therefor
consid
result
overal
mdx
mice
treat
four
core
appear
demonstr
improv
dystrophin
product
exon
skip
ta
quadricep
heart
muscl
compar
previou
lead
candid
addit
core
exhibit
evid
toxic
assess
plasma
level
relev
toxic
biomark
alanin
aminotransferas
aspart
aminotransferas
creatin
kinas
see
supplementari
figur
blood
urea
nitrogen
creatinin
level
similar
untreat
mdx
level
see
supplementari
figur
treatment
group
exhibit
similar
biomark
level
untreat
control
addit
need
identifi
pippmo
high
effici
cardiac
deliveri
aim
better
defin
element
hydrophob
core
pip
peptid
import
heart
deliveri
end
pip
peptid
contain
partial
delet
hydrophob
core
aa
remov
tyrosin
aa
remov
isoleucin
tyrosin
synthesis
pmo
conjug
figur
follow
treatment
mdx
mice
immunohistochem
stain
perform
reveal
dystrophin
express
skelet
muscl
ta
diaphragm
delet
figur
quantif
immunohistochem
stain
reveal
lowest
dystrophin
restor
quadricep
close
follow
compar
figur
b
tabl
similarli
display
lowest
dystrophin
restor
diaphragm
recoveri
score
conjug
heart
low
indic
poor
effici
rs
figur
result
corrobor
pcr
western
blot
analys
rtpcr
repres
imag
figur
qrtpcr
exon
skip
result
figur
indic
reduc
exon
skip
mdx
mice
treat
conjug
quadricep
diaphragm
neglig
exon
skip
heart
western
blot
analysi
reveal
ineffici
dystrophin
protein
product
ta
quadricep
muscl
neglig
dystrophin
restor
heart
figur
supplementari
figur
result
show
length
hydrophob
core
crucial
good
heart
dystrophin
product
also
activ
muscl
group
therefor
arginin
content
cpp
alon
sole
predictor
dystrophin
product
exon
skip
effici
class
peptid
reposit
arginin
flank
region
core
unexpectedli
welltoler
gave
similar
result
conjug
two
conjug
thu
synthes
figur
deriv
contain
second
arginin
residu
move
second
flank
region
central
hydrophob
core
contain
invers
hydrophob
region
singl
arginin
locat
alter
within
core
surprisingli
chang
hydrophob
core
result
reduct
dystrophin
express
heart
also
tissu
observ
immunohistochem
stain
figur
quantif
thereof
figur
c
immunohistochem
stain
repres
imag
reveal
dystrophin
posit
fiber
tissu
except
ta
quadricep
figur
refer
quantif
significantli
differ
untreat
mdx
quadricep
diaphragm
supplementari
figur
deriv
significantli
differ
untreat
mdx
heart
muscl
illustr
gener
ineffici
two
peptid
similarli
deriv
show
reduc
effici
exon
skip
illustr
repres
rtpcr
imag
figur
qrtpcr
analys
figur
supplementari
figur
tissu
western
blot
reveal
neglig
dystrophin
protein
restor
figur
supplementari
figur
tissu
except
ta
muscl
data
show
increas
number
arginin
alter
locat
singl
arginin
hydrophob
region
detriment
heart
well
skelet
muscl
dystrophin
product
promis
therapi
date
sever
debilit
neuromuscular
disord
dmd
treatment
ao
restor
read
frame
dystrophin
premrna
exon
skip
two
ao
current
clinic
trial
earli
promis
result
increas
hope
dmd
patient
howev
studi
involv
administr
high
dose
nake
pmo
mdx
mice
shown
partial
restor
dystrophin
bodywid
skelet
muscl
neglig
correct
necess
correct
dystrophin
heart
ever
appar
follow
studi
wherebi
correct
skelet
phenotyp
result
increas
cardiac
workload
thu
progress
discoveri
cppconjug
pmo
achiev
much
effect
dystrophin
correct
mdx
mice
nake
pmo
brought
renew
promis
enhanc
ao
efficaci
improv
cellular
vivo
deliveri
previous
report
promis
peptidepmo
candid
capabl
restor
dystrophin
protein
high
level
muscl
type
includ
heart
follow
singl
mgkg
addit
argininerich
sequenc
pip
peptid
contain
hydrophob
section
present
previou
bpeptid
seem
like
respons
improv
heart
activ
seri
develop
deriv
attempt
cast
light
aspect
hydrophob
core
requir
heart
dystrophin
product
also
identifi
even
activ
pippmo
conjug
studi
use
moder
singl
dose
administr
regimen
produc
interest
sometim
surpris
result
key
find
mainten
length
hydrophob
core
region
imper
good
heart
dystrophin
product
one
might
imagin
diminish
effici
dystrophin
restor
heart
sequenti
amino
acid
delet
core
might
correl
result
lower
hydrophob
henc
reduc
capac
enter
howev
vitro
result
would
suggest
construct
capabl
enter
cell
fulli
capabl
exon
skip
muscl
cell
figur
thu
length
hydrophob
core
must
affect
differ
paramet
essenti
vivo
heart
deliveri
enhanc
uptak
whole
heart
slice
fluoresc
label
compar
bpmo
suggest
instead
cross
anoth
barrier
exampl
endotheli
line
heart
heart
studi
continu
may
help
address
issu
surpris
perhap
also
loss
dystrophin
product
muscl
type
suggest
hydrophobiccation
balanc
andor
precis
space
hydrophob
cation
residu
cpp
impos
subtl
effect
vivo
deliveri
paramet
anoth
clear
conclus
aris
analogu
specif
order
hydrophob
residu
within
hydrophob
core
less
import
maintain
heart
dystrophin
product
sinc
invert
sequenc
singl
substitut
equal
hydrophob
residu
scrambl
sequenc
least
activ
effici
heart
muscl
group
figur
supplementari
figur
result
provid
evid
hydrophob
core
pip
peptid
unlik
contain
particular
amino
acid
sequenc
recogn
specif
receptor
membran
barrier
requir
penetr
heart
tissu
instead
core
act
hydrophob
spacer
kind
surpris
howev
induc
dystrophin
splice
protein
restor
heart
muscl
indic
western
qrtpcr
result
note
significantli
differ
immunohistochem
stain
quantif
peptid
one
arginin
residu
move
hydrophob
core
also
result
align
hydrophob
x
residu
adjac
core
xyrfli
one
might
expect
heart
dystrophin
product
complet
lost
conjug
sinc
cation
amino
acid
arginin
includ
core
contrast
heart
activ
lost
xilfri
core
doubl
arginin
core
conjug
xyrfrlix
core
unexpectedli
dystrophin
product
also
lost
quadricep
diaphragm
unanticip
inconsist
within
activ
result
loss
activ
perhap
best
explain
realiz
precis
space
arginin
residu
within
pip
peptid
respect
outer
hydrophob
amino
acid
spacer
x
b
inner
hydrophob
core
residu
may
drastic
alter
pharmacolog
properti
conjug
might
occur
alter
cationichydrophob
balanc
altern
due
secondari
tertiari
structur
chang
pippmo
could
turn
affect
serum
protein
bind
anoth
paramet
alter
circulatori
halflif
could
affect
abil
travers
barrier
requir
penetr
muscl
tissu
subtl
effect
requir
widerang
pharmacolog
biophys
studi
upon
current
embark
complet
understand
role
hydrophob
core
within
pip
peptid
one
would
ideal
wish
studi
activ
pharmacolog
biophys
paramet
much
larger
rang
sequencevari
pippmo
conjug
need
multimg
synthesi
conjug
well
avail
larg
number
mdx
mice
necessarili
limit
scope
current
studi
gratifi
even
rel
small
number
conjug
test
interest
result
emerg
sever
conjug
shown
promis
dystrophin
product
activ
even
beyond
previou
candid
interestingli
analysi
serum
sampl
one
treatment
show
partial
normal
three
mirna
near
wild
type
level
follow
singl
mgkg
administr
robert
et
al
relat
greatli
promis
would
consid
optim
peptid
yet
still
demonstr
signific
therapeut
effect
group
peptid
new
lead
provid
good
basi
identif
pippmo
candid
suitabl
detail
physiolog
studi
muscl
heart
function
well
thorough
toxic
profil
includ
dose
escal
studi
anticip
one
pippmo
proceed
clinic
trial
synthesi
peptidepmo
conjug
peptid
synthes
standard
fmoc
chemistri
purifi
highperform
liquid
chromatographi
pmo
sequenc
purchas
gene
tool
llc
corval
peptid
conjug
pmo
amid
linkag
end
pmo
follow
purif
highperform
liquid
chromatographi
analyz
malditof
ms
previous
describ
preliminari
full
detail
synthesi
includ
improv
experiment
procedur
describ
detail
supplementari
materi
method
peptidepmo
conjug
dissolv
steril
water
filter
cellulos
acet
membran
use
conjug
pmo
found
predominantli
stabl
similar
stabil
serum
hour
seen
highperform
liquid
chromatographi
malditof
mass
spectral
analysi
conjug
show
similar
degrad
pattern
intact
conjug
still
observ
hour
data
shown
vitro
assay
exon
skip
mdx
mous
myotub
mdx
myotub
prepar
incub
peptidepmo
conjug
absenc
transfect
agent
concentr
method
describ
product
nest
rtpcr
total
isol
rna
examin
electrophoresi
agaros
gel
quantif
transcript
level
calcul
use
densitometri
mt
cell
viabil
test
promega
madison
wi
show
surviv
highest
concentr
peptidepmo
conjug
use
studi
data
shown
anim
intraven
inject
four
half
month
old
mdx
mice
use
experi
n
experi
carri
biomed
scienc
unit
univers
oxford
accord
procedur
author
uk
home
offic
conjug
prepar
salin
solut
final
dose
mgkg
total
volum
administ
via
tail
vein
anaesthet
mice
two
week
later
mice
sacrif
inhal
muscl
tissu
harvest
snapfrozen
cool
isopentan
storag
immunohistochemistri
quantif
dystrophin
express
transvers
section
tissu
sampl
cut
thick
examin
dystrophin
express
dystrophin
visualis
quantif
section
costain
rabbitantidystrophin
abcam
cambridg
rat
antilaminin
sigma
st
loui
mo
detect
goatantirabbit
immunoglobulin
g
alexa
goatantirat
immunoglobulin
g
secondari
antibodi
respect
invitrogen
carlsbad
ca
imag
captur
use
leica
dm
irb
microscop
axiovis
softwar
carl
zeiss
cambridg
uk
quantit
immunohistochemistri
perform
previous
repres
imag
treatment
taken
quantif
four
repres
frame
dystrophin
correl
laminin
taken
section
n
quadricep
diaphragm
heart
treatment
use
imagepro
softwar
region
interest
randomli
place
laminin
imag
overlaid
correspond
dystrophin
imag
minimum
maximum
fluoresc
intens
region
record
treatment
intens
differ
calcul
region
correct
background
fluoresc
untreat
mdx
treat
mdx
normal
valu
plot
scatter
graph
rel
intens
mean
calcul
use
multilevel
statist
model
use
valu
percentag
recoveri
score
calcul
implement
follow
equat
describ
treatnmd
websit
http
dystrophin
recoveri
treat
mdx
micedystrophin
recoveri
untreat
mdx
mice
dystrophin
recoveri
micedystrophin
recoveri
untreat
mdx
mice
stain
dystrophin
associ
protein
perform
previous
use
mom
block
kit
vector
lab
burlingam
ca
novocastra
newcastleupontyn
uk
antibodi
dilut
neuron
nitric
oxid
synthas
stain
perform
use
goat
antirabbit
antibodi
abcam
exon
skip
mdx
mous
tissu
total
rna
extract
control
treat
mous
tissu
use
trizol
reagent
invitrogen
follow
manufactur
instruct
rtpcr
four
hundr
nanogram
rna
templat
use
revers
transcript
reaction
use
one
step
rtpcr
kit
qiagen
hilden
germani
genespecif
primer
ex
fwd
aat
tct
gcc
aat
tgc
tga
rev
ttc
agc
ttg
tgt
cat
cycl
condit
minut
follow
cycl
second
minut
minut
two
microlit
cdna
amplifi
nest
pcr
qiagen
pcr
kit
use
follow
cycl
condit
second
minut
minut
cycl
ex
fwd
ccc
agt
cta
cca
ccc
tat
cag
agc
rev
cct
gcc
ttt
aag
gct
tcc
tt
pcr
product
examin
electrophoresi
agaros
gel
quantit
real
time
pcr
two
microgram
rna
revers
transcrib
use
high
capac
cdna
synthesi
kit
appli
biosystem
branchburg
nj
exon
skip
qpcr
perform
use
syber
green
kit
appli
biosystem
primer
set
idt
stepon
plu
realtim
pcr
system
appli
biosystem
primer
set
use
follow
total
dystrophin
transcript
fwd
gccatagcacgagaaaaagc
rev
gcattaacaccctcatttgc
dmd
transcript
fwd
gcg
cta
tca
gga
gac
aat
gag
rev
gtt
ttt
atg
tga
ttc
tgt
aat
ttc
cc
plasmid
total
dystrophin
delta
skip
use
standard
curv
protein
extract
western
blot
control
treat
muscl
sampl
homogenis
lysi
buffer
compris
mmoll
ph
sodium
dodecyl
sulphat
complement
sampl
heat
minut
centrifug
remov
supernat
protein
level
measur
bradford
assay
sigma
quantifi
use
bsa
standard
ten
fifteen
microgram
protein
untreat
treat
mdx
sampl
concentr
protein
posit
control
load
onto
trisacet
gel
protein
blot
onto
polyvinyliden
fluorid
membran
probe
dystrophin
use
novocastra
load
control
sigma
antibodi
primari
antibodi
detect
bind
horseradish
peroxidaseconjug
antimous
immunoglobulin
g
lumigen
western
blot
imag
licor
bioscienc
lincoln
ne
analyz
use
odyssey
imag
system
clinic
biochemistri
plasma
sampl
taken
jugular
vein
mdx
mice
immedi
follow
sacrific
inhal
analysi
toxic
biomark
perform
clinic
patholog
lab
mari
lyon
centr
mrc
harwel
uk
statist
analysi
data
report
mean
valu
sem
multilevel
repeat
measur
model
implement
studi
multilevel
statist
approach
build
upon
tradit
statist
method
increasingli
implement
social
medic
biolog
model
use
studi
take
account
multipl
rel
intens
unit
level
mous
level
treatment
level
perform
immunohistochem
stain
quantif
exampl
mdx
untreat
mice
mice
appli
constantfix
paramet
treatment
wildtyp
control
compar
follow
boxcox
power
transform
perform
ensur
normal
distribut
statist
analysi
perform
use
mlwin
version
